| Name | Title | Contact Details |
|---|
Aspire General Insurance is a California-based insurance provider that specializes in private passenger auto insurance. Founded in 2012, the company operates in Arizona, California, and Michigan, offering services in both English and Spanish. Aspire has an AM Best rating of B++ (Good) with a Stable outlook, indicating its financial stability. The company focuses on liability and physical damage coverage for private passenger vehicles. It provides 24/7 claims reporting and in-house processing, along with online and mobile tools for policy management, payments, and document access. Aspire offers flexible payment options, including low down payments and installment plans. Their customer support features bilingual call centers and automated solutions for policy updates and claims tracking, ensuring a responsive service experience.
NCD is dedicated to improving lives by driving better health, providing an exceptional experience, and Spreading the Smile. As the costs of dental and vision insurance continue to increase across the country, our mission is to provide comprehensive dental and vision care thats accessible, quick to obtain, and simple to use. Whether youre uninsured or under-insured, NCD has a plan that fits your dental and vision needs.
People always ask, what does strategic communications mean? For us, it means finding interesting, smart, and inventive ways to get information to the right people. It means streamlining programs that are cumbersome, messy, and confusing and making them easy to use. It means identifying dated layout and design and creating content that is stunning and engaging. Based in Natick, MA, Strategic Communications, Inc. (StratComm) has served the marketing, communications, training, and project management needs of nationwide Fortune 500 companies, many federal agencies, and all branches of the Armed Forces for over 45 years. Our team works with a variety of clients and delivers an array of services. We create high-quality publications, both print and electronic, and training platforms for leading corporations and organizations such as IBM, VMware, the United States Navy and Air Force, the U.S. Department of State, Veterans Affairs, the U.S. Treasury, and many other important agencies and organizations. We also manage large programs for the federal government utilizing emerging technologies. Two examples are online training and testing programs for U.S. Embassies worldwide and program management for the Social Security Administration. Many high profile clients contract with StratComm to update the design and content of their websites, brochures, annual reports, and web apps. Our team is constantly seeking newer technologies and developing efficiencies to better serve our clients. Within our headquarters, we house a core team of dedicated professionals who administer our programs. Together, we manage varied projects and communications challenges for both large and small clients. Strategically, of course.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.